163 related articles for article (PubMed ID: 17163297)
1. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
Rosery H; Bergemann R; Marx SE; Boehnke A; Melnick J; Sterz R; Williams L
Clin Drug Investig; 2006; 26(11):629-38. PubMed ID: 17163297
[TBL] [Abstract][Full Text] [Related]
2. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
Fiedler R
Clin Drug Investig; 2007; 27(12):865-6. PubMed ID: 18020546
[No Abstract] [Full Text] [Related]
3. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.
Nuijten M; Andress DL; Marx SE; Sterz R
Curr Med Res Opin; 2009 May; 25(5):1221-34. PubMed ID: 19335321
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
[TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model.
Nuijten M; Andress DL; Marx SE; Curry AS; Sterz R
Clin Drug Investig; 2010; 30(8):545-57. PubMed ID: 20586517
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective.
Menezes FG; Abreu RM; Itria A
J Bras Nefrol; 2016; 38(3):313-319. PubMed ID: 27737389
[TBL] [Abstract][Full Text] [Related]
7. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.
Hansen D; Brandi L; Rasmussen K
BMC Nephrol; 2009 Sep; 10():28. PubMed ID: 19778452
[TBL] [Abstract][Full Text] [Related]
8. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis.
Zhang Z; Cai L; Wu H; Xu X; Fang W; He X; Wang X; Li X
Front Public Health; 2021; 9():712027. PubMed ID: 34368073
[No Abstract] [Full Text] [Related]
9. Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital.
Manjarres L; Sanchez P; Cabezas MC; Fornasini M; Freire V; Albert A
BMC Health Serv Res; 2016 Aug; 16(1):443. PubMed ID: 27566059
[TBL] [Abstract][Full Text] [Related]
10. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
11. Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan.
Gal-Moscovici A; Sprague SM
Clin Drug Investig; 2007; 27(2):105-13. PubMed ID: 17217315
[TBL] [Abstract][Full Text] [Related]
12. Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected].
Nuijten M; Roggeri DP; Roggeri A; Novelli P; Marshall TS
Clin Drug Investig; 2015 Apr; 35(4):229-38. PubMed ID: 25724153
[TBL] [Abstract][Full Text] [Related]
13. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M
J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
[TBL] [Abstract][Full Text] [Related]
14. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial.
Hansen D; Rasmussen K; Danielsen H; Meyer-Hofmann H; Bacevicius E; Lauridsen TG; Madsen JK; Tougaard BG; Marckmann P; Thye-Roenn P; Nielsen JE; Kreiner S; Brandi L
Kidney Int; 2011 Oct; 80(8):841-50. PubMed ID: 21832979
[TBL] [Abstract][Full Text] [Related]
15. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.
Hansen D; Rasmussen K; Pedersen SM; Rasmussen LM; Brandi L
Nephrol Dial Transplant; 2012 Jun; 27(6):2263-9. PubMed ID: 22140123
[TBL] [Abstract][Full Text] [Related]
16. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
17. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
18. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease.
Cardoso MMA; Machado-Rugolo J; Lima SAM; Andrade LGM; Curado DSP; Ponce D
J Bras Nefrol; 2023; 45(1):95-101. PubMed ID: 35980102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
